Adolescents and HIV Vaccine Trials
Author(s) -
LindaGail Bekker,
Heather B. Jaspan,
James McIntyre,
Robin Wood,
Glenda Gray
Publication year - 2005
Publication title -
journal of the international association of physicians in aids care
Language(s) - English
Resource type - Journals
eISSN - 1557-0886
pISSN - 1545-1097
DOI - 10.1177/1545109705284836
Subject(s) - medicine , confidentiality , human immunodeficiency virus (hiv) , hiv vaccine , clinical trial , proxy (statistics) , family medicine , parental consent , vaccine trial , informed consent , alternative medicine , computer security , pathology , machine learning , computer science
Adolescents worldwide are at high risk for HIV, which makes them essential candidates for HIV vaccine trials. However, enrollment of adolescents into such trials has implications for trial sites. Adolescents are considered vulnerable subjects and require proxy consent in addition to their assent, which brings issues of confidentiality and access into play. HIV vaccine trial sites often do not have experience recruiting and retaining adolescents, and creating youth-friendly environments that are comfortable for guardians. This includes development of education materials that target both youth and their parents. Because these trials are of minimal individual benefit, sites will likely need to provide service in the form of health care and supportive structures to adolescents. Finally, a number of trial design options exist, and researchers will need to balance the risks and benefits of each, as for all issues surrounding the involvement of adolescents in HIV vaccine trials.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom